Leone Sebastiano, Noviello Silvana, Esposito Silvano
Department of Infectious Diseases, Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi d'Aragona, Università di Salerno, Largo Città di Ippocrate, 84131, Salerno, Italy.
Infection. 2016 Jun;44(3):273-81. doi: 10.1007/s15010-015-0836-0. Epub 2015 Sep 1.
Enterococci are common causes of infective endocarditis (IE) in both health care and community-based setting. Enterococcal IE requires bactericidal therapy for an optimal outcome. For decades, cell-wall-active antimicrobial agents (penicillins or vancomycin) in combination with aminoglycosides were the cornerstone of the treatment; however, the emergence of antibiotic resistance has significantly reduced the efficacy of these regimens.
Data for this review were identified by searches of MEDLINE and references from relevant articles on antibiotic combination regimens for the treatment of enterococcal IE. Abstracts presented in scientific conferences were not searched for.
New effective and safe combination treatments, including double-β-lactam and daptomycin/β-lactam combination, are proving useful for the management of IE due to enterococci.
肠球菌是医疗保健机构和社区环境中感染性心内膜炎(IE)的常见病因。肠球菌性IE需要采用杀菌疗法以获得最佳疗效。几十年来,细胞壁活性抗菌药物(青霉素或万古霉素)联合氨基糖苷类药物一直是治疗的基石;然而,抗生素耐药性的出现显著降低了这些治疗方案的疗效。
本综述的数据通过检索MEDLINE以及治疗肠球菌性IE的抗生素联合治疗方案相关文章的参考文献来确定。未检索科学会议上发表的摘要。
新的有效且安全的联合治疗方法,包括双β-内酰胺类和达托霉素/β-内酰胺类联合治疗,已被证明对治疗肠球菌引起的IE有效。